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Abstract: To determine if candidate cancer biomarkers have utility in a clinical setting, validation using immunohistochemical methods 
is typically done. Most analyses of such data have not incorporated the multivariate nature of the staining profiles. In this article, we 
consider modelling such data using recently developed ideas from the machine learning community. In particular, we consider the 
joint goals of feature selection and classification. We develop estimation procedures for the analysis of immunohistochemical profiles 
using the least absolute selection and shrinkage operator. These lead to novel and flexible models and algorithms for the analysis of 
compositional data. The techniques are illustrated using data from a cancer biomarker study.
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Introduction
The development of high-throughput assays such as 
mass spectrometry and gene expression microarrays 
has led to the generation of large numbers of candidate 
biomarkers  in  current  medical  research.  However, 
while  such  results  and  signatures  tend  to  provide 
great  potential  for  disease  prognosis,  translating 
the  discovery  into  a  clinically  useful  biomarker 
requires more investigation. An important first step 
typically  is  to  validate  the  finding  using  so-called 
immunohistochemical staining patterns.
In immunohistochemical studies, staining patterns 
of  the  biomarker  are  measured  across  a  variety  of 
samples. One common way this is done is using a tissue 
microarray.1 In this scheme, the “spots” on the glass 
slide represent tumor cores from different patients, and 
an antibody for the protein of interest is applied to the 
slide. The staining patterns are then correlated with 
patient characteristics. In most instances, the staining 
is assessed by a pathologist, who assigns a score on 
an ordinal scale, with larger values corresponding to 
higher levels of staining. Note that this structure is quite 
different from an expression microarray, in which the 
spots are individual genes and proteins of interest, while 
what is hybridized to the slide is a single sample.
Typically,  an  analysis  of  such  data  requires  the 
creation  of  a  univariate  score  measuring  staining 
intensity for each sample. Then the score is associated 
with  clinical  outcomes  using  standard  testing  and 
regression  methods.  For  example,  if  the  clinical 
outcome  is  binary,  one  could  use  a  parametric  or 
non-parametric  two-sample  test  for  association. 
Alternatively,  one  could  fit  a  linear  regression  of 
staining intensity on clinical outcome or a logistic 
regression of the outcome on staining intensity.
As noted by Etzioni et al2 the staining of tumor 
samples to the antibody is not completely homogeneous. 
What  is  available  for  certain  scoring  systems  is  a 
multivariate profile of percent of tumor cells staining 
at each level of the various scoring categories. As an 
example, we consider tissue microarray data from a 
candidate prostate cancer biomarker, LIMK1.3 LIMK1 
is  a  dual  specificity  novel  serine/threonine  kinase 
which modulates actin dynamics through inactivation 
of the actin depolymerizing protein cofilin.
The function of LIMK1 in reorganization of the 
cytoskeleton  has  been  studied  extensively  during 
developmental defects.4,5 Recently, a role of LIMK1 
in  progression  and  invasiveness  of  breast  and 
prostate cancer has been predicted.6,7 In this paper, we 
explore the status of LIMK1 staining in the nucleus 
and  cytoplasm  as  it  relates  to  aggressiveness  of 
prostate cancer.
In this dataset, there were five staining categories, 
and  50  samples  were  profiled  for  LIMK1  nuclear 
staining.  The  data  for  five  randomly  chosen 
observations  are  given  in  Table  1.  Note  that  by 
definition, the percentages within each row must add 
up to one. Such data are referred to as compositional 
data.8 A major advance by Etzioni et al2 was to advance 
the use of composition data analytic techniques for the 
analysis of immunohistochemical data. They propose 
the use of Bayesian inference for the so-called logistic 
normal distribution for compositional data. However, 
fitting their model requires customized software that is 
typically not available to data analysts. In this article, 
we discuss the model proposed by Etzioni et al2 and 
show that it is in fact equivalent to a particular linear 
discriminant  analysis  model.  Linear  discriminant 
analysis  (LDA),  pioneered  by  Fisher,9  has  been  a 
popular model in the classification literature. Software 
for  fitting  LDA  is  available  in  most  mainstream 
statistical  packages,  such  as  MINITAB,  SAS  and 
Splus/R. Thus, the first aim of the article is to show 
that one can in fact fit the model of Etzioni et al2 using 
LDA methods. A second goal of the article is to jointly 
perform  classification  and  feature  selection  within 
this class of LDA models. Such an approach would 
allow  for  the  automated  inclusion  of  informative 
and  exclusion  of  non-informative  categories  for 
discriminating samples. In the context of the tissue 
microarray example, this means that we want to find 
which  staining  categories  that  are  informative  for 
predicting  aggressiveness. This  will  be  done  using 
the lasso penalty described initially by Tibshirani,10 in 
conjunction with a model selection strategy.
The structure of this article is as follows. In Results 
and Discussion, we outline the data structures and 
discuss  the  logistic  normal  model  formulation  of 
Etzioni  et al2  for  analysis  of  immunohistochemical 
profiles and equivalence with LDA. We also describe 
the lasso algorithm of Tibshirani.10 The methods are 
then applied to the motivating dataset. In the Methods 
section, we describe the optimal scoring algorithm 
for  converting  the  classification  problem  of  linear 
discriminant  analysis  into  a  regression  problem.11 Joint variable selection and classication with immunohistochemical data
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This will allow for the fusion of the classification using 
multivariate  staining  profiles  along  with  automatic 
lasso-based selection of staining categories that are 
informative.  In  addition,  we  describe  methods  for 
additional covariate adjustment and model selection 
within this framework.
Results and Discussion
data structures and logistic  
normal model
We will be assuming that we have data (Di, Yi, X), 
i  =  1, ...,  n,  a  random  sample  from  (D,  Y,  X), 
where D denotes the group status, Y ≡ (Y1, ..., Yp) is a 
p-dimensional staining profile, and X is a q-dimensional 
vector of covariates. D will take values 0 and 1. We 
let s1, ..., sp denote the scores assigned to (Y1, ..., Yp); 
typically, we take (s1, ..., sp) to be (0, ..., p - 1) or 
(1, ..., p). It is assumed that Yi (i = 1, ..., p) takes values 
in (0, 1) and that  Yi i
p
 = 1
= ∑ 1 . While Y is assumed to 
have all non-zero components, in practice zeroes do 
exist.  We  follow  the  recommendations  of  Etzioni 
et al2 and add in a random noise term.
Logistic normal Distribution  
for Compositional Profiles
Define the (p - 1)-dimensional vector
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1  Note that we have transformed 
the p-dimensional vector Y into a ( p - 1)-dimensional 
vector Z in order to remove the constraint Y Yj j
p
.=
= ∑ .
1  
In addition, the components of Z are nonnegative. Thus, 
transformed vectors are multivariate measurements 
on  the  product  space  (0,  ∞)(p-1).  The probabilistic 
model proposed in Etzioni et al2 for the analysis of 
immunohistochemical  profiles  is  to  assume  that 
conditional on D,
  Z D N D ∼ ( , ), µ ∑   (2)
where µD is a ( p - 1)-dimensional mean vector and 
Σ is  a  covariance  matrix. The  induced  distribution 
for (Y1/Y, ..., YP/Y) is referred to as the logistic normal 
distribution  in  the  compositional  data  analysis 
literature.8,12 While interpretation for the parameters 
on the transformed scale (i.e. Z) is easy, it is harder to 
interpret on the original scale.
In  terms  of  analyzing  immunohistochemical 
profiles, Etzioni et al2 adopted a hierarchical model in 
which priors were placed on µD and Σ. They then used 
a  Markov  Chain  Monte  Carlo  (MCMC)  sampling 
algorithm to sample from the the posterior distribution 
of µD. It was used to construct a 95% credible interval 
for  mean  shifts  for  the  log-transformed  profile. 
An easier estimation procedure that does not require 
implementing a Gibbs sampling algorithm is to fit a 
linear discriminant analysis model to the transformed 
data Z. This can be performed using virtually any 
standard statistical software package. The estimated 
linear  discriminants  from  performing  the  linear 
discriminant analysis can be used in several ways. 
First,  they  can  be  used  as  a  visualization  method. 
Second,  they  can  serve  as  a  data-driven  summary 
score on which further analysis can be performed.
One  also  notes  that  (2)  can  be  generalized  to 
allow  for  proportional  covariance  matrices  across 
populations.  This  would  then  necessitate  fitting  a 
quadratic linear discriminant analysis model to Z.
Lasso estimation
Shifting  gears,  we  discuss  the  Least  Absolute 
Shrinkage  and  Selection  (LASSO)  algorithm 
Table 1. Summary of staining data for five randomly chosen observations from prostate cancer data.
Observation category 1 category 2 category 3 category 4 category 5
1 1.000 0.00 0.00 0.000 0
2 0.950 0.05 0.05 0.000 0
3 0.600 0.30 0.10 0.000 0
4 0.600 0.40 0.40 0.000 0
5 0.950 0.05 0.05 0.000 0ghosh and Chakrabarti
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proposed by Tibshirani.10 Suppose we wished to fit 
the linear regression model: E(Ui|Yi) = βTYi, where 
(U1, ..., Un)  are  continuous  variables,  and  β  is  an 
unknown p-dimensional vector of unknown regression 
coefficients to be estimated. The LASSO solution is 
given by
 
ˆ argmin | |, β β β L i
T
i
i
n
j
i
p
U = - ( ) +
= = ∑ ∑ Y
2
1 1
λ
 
where λ  0 is a penalty parameter, and βj denotes 
the  jth  component  of  β.  Tibshirani10  showed  that 
placing an L1 constraint on the sum of the magnitude 
of the regression coefficients yielded sparsity in the 
estimates  of  β.  To  be  specific,  for  certain  values 
of λ, it is possible for the lasso estimate of β to be 
identically  zero.  Further  details  on  the  numerical 
algorithm implemented here is given in Methods.
LIMK1 Biomarker study
Using the procedures described above as well as in 
the  Methods  section,  we  now  consider  a  real-life 
application.  The  immunohistochemical  data  come 
from  a  putative  prostate  cancer  biomarker,  LIM 
kinase  1  (LIMK1).3  In  this  study,  the  expression 
profile of LIMK1 was determined using a prostate 
tumor  tissue  array  comprising  50  samples  from 
tumors at different stages of progression. The pool 
of  samples  in  the  array  included  three  uninvolved 
prostate tissues for comparison. TNM classification 
of tumors in the TMA indicated that 62% patients had 
histories of either lymph node or distant metastasis at 
the time of surgery or biopsy, and 88% of the tumors 
had Gleason scores of 7 or above. Gleason score (GS) 
is an aggregate measure of the aggressiveness of the 
tumor. It is composed of a major and minor Gleason 
score, each of which is scored on a scale of one to 
five. We dichotomized Gleason score as less than or 
greater than or equal to eight.
Analyses of nuclear staining are considered first. 
Scatterplots  of  the  multivariate  nuclear  staining 
profiles by pairwise category comparison are given 
in Figure 1. To associate staining with the clinical 
parameters  (presence  of  metastases,  Gleason 
score),  we  used  the  product  score,  multiplying 
the  percentage  staining  by  the  staining  intensity. 
Boxplots of the product score for nuclear staining 
versus  presence  of  metastases  and  Gleason  score 
are  provided  in  Figures 2  and  3.  While  Figure  2 
indicates that metastatic tumors have higher nuclear 
staining  relative  to  non-metastatic  tumors,  there 
is  less  difference  in  nuclear  staining  across  the 
different Gleason score categories. A t-test reveals 
the  differences  corresponding  to  the  boxplot  in 
Figure 2 to be statistically non-significant (P = 0.32 
for  presence  of  metastases),  while  an  analysis  of 
variance  yields  the  association  between  nuclear 
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Figure 1. Pairwise plots of nuclear staining by staining category for the 
LIMK1 study.
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Figure 2. Boxplot of product score for LIMK1 nuclear staining (vertical 
axis) by presence of metastases (horizontal axis). 0 indicates absence of 
metastases, while 1 indicates presence of metastases.Joint variable selection and classication with immunohistochemical data
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staining and Gleason score to also be nonsignificant 
(P = 0.31).
A series of logistic classification models using the 
proposed  methods  were  run;  they  are  summarized 
in Table  1.  Based  on  the  analyses  we  find  that  if 
we use nuclear staining profile to predict presence 
of metastases, then all four staining categories are 
informative. Using the BIC criterion, there was no 
improvement by including presence of metastases as 
a covariate. On the other hand, if one wishes to use 
nuclear staining to predict Gleason score, then only 
the third staining category is informative. There is no 
improvement by including presence of metastases as 
a covariate.
Next,  we  considered  analyses  based  on 
cytoplasmic staining intensity. Pairwise scatter-plots 
of cytoplasmic staining are given in Figure 4. As with 
nuclear  staining,  we  used  the  product  score  for 
associating  the  immunohistochemcial  profile for 
cytoplasmic staining with Gleason score and presence 
of metastases. The boxplots of the LIMK1 cytoplasmic 
staining product score by presence of metastases and 
Gleason status are given in Figures 5 and 6. Analyses 
analogous  to  those  for  nuclear  staining  reveal 
nonsignificant associations (P = 0.75 and P = 0.40 
for  presence  of  metastases  and  Gleason  score, 
respectively).
The  logistic  normal  models  results  for  analysis 
using the cytoplasmic staining profiles are given in 
Table 2. For predicting presence of metastases, only 
the first staining category is needed. However, if we 
seek to adjust for Gleason score, then categories 1, 3, 
and 4 are needed. However, the BIC shows that the 
model  fit  worsens.  If  we  use  cytoplasmic  staining 
to predict Gleason score, then categories 2, 3, and 4 
are  selected  by  the  LASSO  procedure.  Including 
presence of metastases does not improve the model 
fit. Comparing across the models listed in the Table, 
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Figure 3. Boxplot of product score for LIMK1 nuclear staining (vertical 
axis) by gleason score (horizontal axis).
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Figure 4. Pairwise plots of cytoplasmic staining by staining category for 
the LIMK1 study.
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Figure  5.  Boxplot  of  product  score  for  LIMK1  cytoplasmic  staining 
(vertical axis) by presence of metastases (horizontal axis). 0 indicates 
absence of metastases, while 1 indicates presence of metastases.ghosh and Chakrabarti
108  Biomarker Insights 2009:4
we see that models with fewer staining categories 
selected tend to have better model fit. This supports the 
use of the LASSO algorithm for automating variable 
selection while fitting the logistic normal model to 
the immunohistochemical profiles. This also suggests 
that the proposed methodology, which in effect can 
fit a reduced submodel of the model of Etzioni et al2 
is a better fit to the data rather than the full model of 
Etzioni et al.2
conclusions
In  this  article,  we  have  explored  a  compositional 
data model initially proposed by Etzioni et al2 that is 
applicable to the modelling of immunohistochemical 
biomarker  data  such  as  those  which  might  arise 
from tissue microarrays. We have shown that it has 
a natural link with linear discriminant analysis, which 
has been very well-studied in the statistical literature. 
Consequently, the Etzioni et al model can be fit using 
standard  software  packages  for  LDA,  after  some 
data manipulations are performed. The inference we 
perform is non-Bayesian, in contrast to the Bayesian 
inference done by Etzioni et al.2
We  also  have  developed  an  automated  variable 
selection  procedure  within  the  class  of  models  by 
incorporating  LASSO  estimation  procedures.  The 
real data example shows that this automated variable 
selection leads to a better fit. We have also outlined 
a model selection strategy in which the Etzioni et al 
model is compared to submodels in which categories 
are suppressed.
While  we  dealt  with  the  situation  in  this  paper 
where D is binary (as did Etzioni et al), the optimal 
scoring  algorithm  can  be  easily  extended  to  deal 
with the case where D has more than two levels. One 
converts D into a n × (G - 1) matrix, where G is the 
number of groups. The regression model that is fit is 
then a multivariate regression in that the response is 
multivariate.
Scientifically,  while  a  score-based  method  such 
as  the  product  score  provides  a  simple  summary 
statistic for staining data that can then be associated 
with clinical parameters in tests of hypotheses and 
regression models, it might oversimplify the data too 
much. This would be especially undesirable if there 
is substantial within-sample staining heterogeneity. 
Thus,  methods  which  explicitly  account  for  the 
multivariate  nature  of  the  staining  offer  a  useful 
alternative. Compositional data methods are one type 
of multivariate approach. What our method allows 
the analyst to do is (1) model the staining profiles in a 
multivariate manner, (2) incorporate clinical variables 
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Figure  6.  Boxplot  of  product  score  for  LIMK1  cytoplasmic  staining 
(vertical axis) by gleason score (horizontal axis).
Table 2. Summary of logistic normal classification models fit using proposed methods in the paper.
staining Intensity Group label covariate Adjustment categories selected BIc
Nuclear Staining Presence of Metastases
Presence of Metastases
gleason score
gleason score
None
gleason score
None
Presence of Metastases
1,2,3,4
1,2,3,4
3
3
17.41
17.77
13.24
16.28
Cytoplasmic Staining Presence of Metastases
Presence of Metastases
gleason score
gleason score
None
gleason score
None
Presence of Metastases
1
1,3,4
2,3,4
2,3,4
13.90
17.77
16.14
16.28Joint variable selection and classication with immunohistochemical data
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as covariates and (3) exclude uninformative staining 
categories.
Methods
Lasso-based optimal scoring algorithm
In  this  section,  we  describe  our  proposal,  which 
entails developing a sparse estimator in the logistic 
normal model for compositional data. This is done 
by  using  the  optimal  scoring  algorithm  of  Hastie 
et al11  to  convert  the  logistic  normal  classification 
problem into a regression problem. This is done in 
the following way:
1. Choose  an  initial  score  matrix  M  satisfying 
M′CPM = I, where Cp = D′D/n, and let M0 = DM.
2. Fit a linear regression model of M0 on Z, yielding 
fitted values M. 
3. Obtain the eigenvector matrix  Φ of Φ of M M; 0 ′ 
the optimal scores are then M M = 0Φ.
The  fitted  values  obtained  at  the  end  of  the 
algorithm are proportional to the linear discriminant 
analysis  coefficients.  To  extend  the  algorithm  so 
that we jointly perform classification and automated 
variable  selection,  we  simply  replace  step  3  of 
the  algorithm  by  LASSO  estimation  of  the  type 
described in Results and Discussion. Based on the 
algorithm, regression coefficients for each variable in 
X will be estimated. Those with estimated regression 
coefficients that are zero are considered unimportant 
variables or features.
We will use the algorithm of Osborne et al13 for 
LASSO estimation. Let σ be the index set, a subset 
of {1, ..., p}. The ith component of β is non-zero if 
and only if I ∈ σ. The algorithm of Osborne et al13 
operates by sequentially updating the index set. Let 
P  denote  the  permutation  matrix  that  arranges  the 
non-zero components of η as the first s components, 
where s is the cardinality of σ. We have that
  β
βσ =





 P
T
0
. 
Let θσ be the sign vector of βσ. At each step of the 
algorithm, β must satisfy the L1 constraint; this can 
be expressed as θ β σ σ
T t ≤ . The optimization problem 
solved by Osborne et al13 is to minimize
  1
2
0
2
1
M h i i
T
i
n
- + ( ) { }
= ∑ Z β  
over h subject to θ β σ σ σ
T t ( ) + ≤ h  and
  h
h
0
=

 

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T σ . 
If the constraint is active, then the optimal solution 
for h is given by the least square method. Let h denote 
the solution, and let (β* = β + h. If sign(β*)σ = θσ, 
then (β* is said to be sign feasible. If (β* is not sign 
feasible, then the following steps are taken:
1. Find the smallest α ∈ (0, 1) such that 0 = βk + αhk 
for a k ∈ σ and set   β β α = + h.
2. One of two steps may be taken here. Either
i.  Set θk = -θk and recompute h. If β + h is sign 
feasible for the revised θ, set (β* = β + h and go to 
step 3. or
ii. Update  σ  by  deleting  k,  resetting  β  and  θσ 
accordingly,  and  recompute  h  for  the  revised 
problem.
3. Iterate between steps 1 and 2 until a sign feasible 
 β  is obtained. Set β β * . = 
Once the sign feasibility is obtained, the optimality 
of the candidate solution is tested. This is done by 
calculating
v
*
* v
v =
-
-
= ( )
Z D Z
Z D Z
T T
T T
T P
( )
( )
,
β
β σ
2
1
where  Zσ  is  the  design  matrix  Z  with  columns 
corresponding to P. By definition, the ith component 
of v1 is θi for 1  i  s. If the absolute magnitude of 
the ith component of v2  1 for 1  i  (p - s), then 
β* is a solution to the lasso problem. Otherwise, the 
following steps are taken:
1. Find the index j such that the jth component of v2 
has the largest magnitude.
2. Update σ by adding j to it and update βσ by adding 
a zero as its last element and βσ by appending the 
jth component of sign(v2).
3. Set (β* = β and iterate between steps 1 and 2.
This  algorithm  has  been  implemented  as  an  R 
function (www.r-project.org) by the first author and 
can be obtained upon request.
Covariate adjustment and model selection
An important question not addressed by Etzioni et al2 
was adjusting for other co-variates in addition to D. ghosh and Chakrabarti
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Since we have expressed the classification problem 
as a regression one via the optimal scoring algorithm, 
we can immediately modify it to account for X:
1. Choose  an  initial  score  matrix  M  satisfying 
M′CPM = I, where Cp = D′D/n, and let M0 = DM.
2. Fit a linear regression model of M0 on X.
3. Compute the residuals from step 2 and regress on 
Z using the LASSO estimation algorithm, yielding 
fitted values M .
4. Obtain  the  eigenvector  matrix  Φ  of  ′ M0M ;  the 
optimal scores are then M = M0Φ.
Notice  that  this  algorithm  forces  X  to  be  inthe 
model so that components of X are not set to zero 
using the LASSO algorithm.
Based on the models, it would be useful to have 
a criterion for performing model selection. We can 
do  this  easily  again  using  the  equivalence  of  the 
classification and regression problem. We simply use 
the formula RSS + p/2 log n, where RSS denotes the 
residual sum of squares from the linear regression 
output in the algorithm, and p denotes the number 
of  variables  that  are  in  the  regression  model.  In 
particular, variables with estimated zero coefficients 
are not counted. Lower values of the criterion indicate 
better model fit. We will refer to this criterion as the 
Bayesian Information Criterion (BIC), a version of 
which was proposed by Schwarz.14 Note that if the 
smallest BIC value corresponds to no variables being 
excluded, then this indicates that the best model fit is 
that of Etzioni et al.2
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